Insulin Prefilled Pens Recalled Due to Missing Label
The recall does not pertain to the interchangeable biosimilars, Semglee (insulin glargine-yfgn) injection, or Insulin Glargine (insulin glargine-yfgn) injection.
Diabetes
Comprehensive Approach Advised for Managing CV Risk in T2DM
In addition to managing all cardiovascular risk factors, providers must consider social determinants of health
ADA Updates Standards of Medical Care in Diabetes for 2022
Updates include recommendation to screen for prediabetes and diabetes in all people starting at age 35 years
Packaging Update Announced for Rybelsus Tablets
The Company is transitioning away from the blister packs to fully recyclable 30-count bottles.
Inequities Seen in GLP-1 RA Use for Type 2 Diabetes in the US
Asian, Black, Hispanic, and low-income patients less likely to receive treatment with a glucagon-like peptide-1 receptor agonist for T2DM
Experts Weigh In on the Best Diets for 2022
An expert panel assessed 40 diets to come up with the final results, examining the evidence behind each diet’s claims.
FDA Approves Biosimilar Insulin Product Rezvoglar
Rezvoglar is a long-acting human insulin analogue.
USPSTF: Evidence Lacking for T2DM Screening in Children
Current evidence is inadequate for assessing benefits and harms of type 2 diabetes screening in children and adolescents
Childhood Vaccination Schedule Not Linked to Type 1 Diabetes
Recommended immunization schedule is not positively associated with the incidence of type 1 diabetes in children
Dasatinib Beneficial in Type 2 Diabetes
Patients treated with dasatinib had mean reduction in serum glucose concentration and relative decrease in body weight
